我武生物1月9日获融资买入2206.14万元，融资余额4.30亿元

Group 1 - The core viewpoint of the news is that I-Wu Biotech has shown positive financial performance with significant growth in revenue and net profit, alongside notable trading activity in its stock [2][3]. - On January 9, I-Wu Biotech's stock price increased by 2.43%, with a trading volume of 219 million yuan. The net financing purchase for the day was 1.11 million yuan, indicating strong investor interest [1]. - As of January 9, the total margin balance for I-Wu Biotech was 431 million yuan, which is 2.63% of its market capitalization, suggesting a high level of leverage compared to the past year [1]. Group 2 - For the period from January to September 2025, I-Wu Biotech reported a revenue of 853 million yuan, representing a year-on-year growth of 16.86%, and a net profit attributable to shareholders of 345 million yuan, up 26.67% [2]. - The company has distributed a total of 913 million yuan in dividends since its A-share listing, with 317 million yuan paid out in the last three years [3]. - As of September 30, 2025, the number of shareholders decreased by 6.22% to 32,400, while the average number of circulating shares per person increased by 6.63% to 14,927 shares [2].